Stock data
Chemomab Therapeutics Ltd. (CMMB)
Chemomab Therapeutics Ltd. (CMMB) reported net income of -US$27.65M for fiscal 2022. The figures below come from the company's SEC filings.
Annual results
Data as of 2022-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2022 | — | — | — | -US$27.65M | — |
| 2021 | — | — | — | -US$12.48M | — |
| 2020 | — | — | — | -US$5.95M | — |
| 2019 | — | — | — | -US$27.12M | — |
| 2018 | — | — | — | -US$13.80M | — |
Quarterly results
Data as of 2023-03-31
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2023-03-31 | — | -US$8.75M | — |
| 2022-12-31 | — | -US$8.27M | — |
| 2022-09-30 | — | -US$8.08M | — |
| 2022-06-30 | — | -US$6.19M | — |
| 2022-03-31 | — | -US$5.10M | — |
| 2021-12-31 | — | -US$5.04M | — |
| 2021-09-30 | — | -US$2.97M | — |
| 2021-06-30 | — | -US$2.77M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.